FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jürgen Mattern

Research Profile

Disorders

Physiology

Chemicals & Drugs

Living Beings

Procedures

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Alexei V Salnikov; Jury Gladkich; Gerhard Moldenhauer; Manfred Volm; Jürgen Mattern; Ingrid Herr
CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Ingrid Herr; Markus W Büchler; Jürgen Mattern
Glucocorticoid-mediated apoptosis resistance of solid tumors.
Thomas Efferth; Badireenath Konkimalla; Yi-Fen Wang; Axel Sauerbrey; Silke Meinhardt; Felix Zintl; Jürgen Mattern; Manfred Volm
Prediction of broad spectrum resistance of tumors towards anticancer drugs.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jürgen Mattern (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Alexei V Salnikov; Jury Gladkich; Gerhard Moldenhauer; Manfred Volm; Jürgen Mattern; Ingrid Herr
CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
International journal of cancer. Journal international du cancer 2010;126(4):950-8.
2009: Ingrid Herr; Markus W Büchler; Jürgen Mattern
Glucocorticoid-mediated apoptosis resistance of solid tumors.
Results and problems in cell differentiation 2009;49():191-218.
2008: Thomas Efferth; Badireenath Konkimalla; Yi-Fen Wang; Axel Sauerbrey; Silke Meinhardt; Felix Zintl; Jürgen Mattern; Manfred Volm
Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2405-12.
2007: Jürgen Mattern; Markus W Büchler; Ingrid Herr
Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy.
Cancer biology & therapy 2007;6(9):1345-54.
2007: Till Wenger; Jürgen Mattern; Tobias L Haas; Martin Sprick; Henning Walczak; Klaus-Michael Debatin; Markus W Büchler; Ingrid Herr
Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects.
Cancer gene therapy 2007;14(3):316-26.
2007: Chengwen Zhang; Till Wenger; Jürgen Mattern; Septimia Ilea; Christian R Frey; Paul Gutwein; Peter Altevogt; Wolfram Bodenmüller; Nikolaus Gassler; Philipp A Schnabel; Hendrik Dienemann; Alexander Marmé; Markus Hohenfellner; Axel Haferkamp; Jesco Pfitzenmaier; Hermann-Josef Gröne; Armin Kolb; Peter Büchler; Markus Büchler; Helmut Friess; Werner Rittgen; Lutz Edler; Klaus-Michael Debatin; Peter H Krammer; Hans Peter Rutz; Ingrid Herr
Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors.
Cancer biology & therapy 2007;6(2):278-87.
2006: Chengwen Zhang; Armin Kolb; Jürgen Mattern; Nikolaus Gassler; Till Wenger; Kerstin Herzer; Klaus-Michael Debatin; Markus W Büchler; Helmut Friess; Werner Rittgen; Lutz Edler; Ingrid Herr
Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy.
Cancer letters 2006;242(1):104-11.
2006: Till Wenger; Jürgen Mattern; Roland Penzel; Nikolaus Gassler; Tobias L Haas; Martin Sprick; Henning Walczak; Peter H Krammer; Klaus-Michael Debatin; Ingrid Herr
Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.
Cell death and differentiation 2006;13(10):1740-51.
2006: Chengwen Zhang; Alexander Marmé; Till Wenger; Paul Gutwein; Lutz Edler; Werner Rittgen; Klaus-Michael Debatin; Peter Altevogt; Jürgen Mattern; Ingrid Herr
Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas.
International journal of oncology 2006;28(2):551-8.
2006: Chengwen Zhang; Armin Kolb; Peter Büchler; Andrew C B Cato; Jürgen Mattern; Werner Rittgen; Lutz Edler; Klaus-Michael Debatin; Markus W Büchler; Helmut Friess; Ingrid Herr
Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer.
BMC cancer 2006;6():61.
2006: Chengwen Zhang; Jürgen Mattern; Axel Haferkamp; Jesco Pfitzenmaier; Markus Hohenfellner; Werner Rittgen; Lutz Edler; Klaus-Michael Debatin; E Groene; Ingrid Herr
Corticosteroid-induced chemotherapy resistance in urological cancers.
Cancer biology & therapy 2006;5(1):59-64.
2005: Nikolaus Gassler; Chengwen Zhang; Till Wenger; Philipp A Schnabel; Hendrik Dienemann; Klaus-Michael Debatin; Jürgen Mattern; Ingrid Herr
Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo.
British journal of cancer 2005;92(6):1084-8.
2004: Jürgen Mattern; Manfred Volm
Imbalance of cell proliferation and apoptosis during progression of lung carcinomas.
Anticancer research 2004;24(6):4243-6.
2004: Stella Okouoyo; Kerstin Herzer; Esat Ucur; Jürgen Mattern; Peter H Krammer; Klaus-Michael Debatin; Ingrid Herr
Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo.
International journal of cancer. Journal international du cancer 2004;108(4):580-7.
2003: Esat Ucur; Jürgen Mattern; Till Wenger; Stella Okouoyo; A Schroth; Klaus-Michael Debatin; Ingrid Herr
Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells.
British journal of cancer 2003;89(11):2155-62.
2003: Jürgen Mattern
Drug resistance in cancer: a multifactorial problem.
Anticancer research 2003;23(2C):1769-72.
2002: Jürgen Mattern; Reet Koomägi; Manfred Volm
Expression of drug resistance gene products during progression of lung carcinomas.
Oncology reports 2002;9(6):1181-4.
2002: Manfred Volm; Reet Koomägi; Jürgen Mattern; T Efferth
Protein expression profiles indicative for drug resistance of non-small cell lung cancer.
British journal of cancer 2002;87(3):251-7.
2002: Manfred Volm; Reet Koomägi; Thomas Efferth; Jürgen Mattern
Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype.
Anticancer research 2002;22(4):2321-4.
2002: Manfred Volm; Reet Koomägi; Jürgen Mattern; Thomas Efferth
Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1843-8.
2002: Jürgen Mattern; Reet Koomägi; Manfred Volm
Characteristics of long-term survivors of untreated lung cancer.
Lung cancer (Amsterdam, Netherlands) 2002;36(3):277-82.
2002: Thomas Efferth; Reet Koomägi; Jürgen Mattern; Manfred Volm
Expression profile of proteins involved in the xenotransplantability of non-small cell lung cancers into athymic nude mice.
International journal of oncology 2002;20(2):391-5.
2002: Manfred Volm; Reet Koomägi; Jürgen Mattern; Thomas Efferth
Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases.
Clinical & experimental metastasis 2002;19(5):385-90.
2001: Jürgen Mattern; Manfred Volm
Clinical estimation of the growth rate of lung cancer.
Anticancer research 2001;21(6A):4067-70.
2001: Jürgen Mattern
Role of angiogenesis in drug resistance.
Anticancer research 2001;21(6B):4265-70.
2000: Manfred Volm; Jürgen Mattern; Reet Koomägi
Angiostatin expression in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3236-40.
2000: Manfred Volm; Jürgen Mattern; Reet Koomägi
Association of telomerase expression with successful heterotransplantation of lung cancer.
International journal of oncology 2000;16(1):31-5.
1999: Reet Koomägi; Jürgen Mattern; Manfred Volm
Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas.
Anticancer research 1999;19(5B):4333-6.
1999: Jürgen Mattern; Reet Koomägi; Manfred Volm
Biological characterization of subgroups of squamous cell lung carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1459-63.
1999: Jürgen Mattern; Reet Koomägi; Manfred Volm
Xenotransplantability of human squamous cell lung cancer in nude mice is not affected by angiogenic factors.
Anticancer research 1999;19(3A):1941-3.
1999: Manfred Volm; Jürgen Mattern; Reet Koomägi
Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas.
Anticancer research 1999;19(3A):1669-71.
1999: Manfred Volm; Jürgen Mattern; R Koomagi
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Oncology reports 1999;6(3):611-5.
1999: Manfred Volm; Reet Koomägi; Jürgen Mattern
Angiogenesis and cigarette smoking in squamous cell lung carcinomas: an immunohistochemical study of 28 cases.
Anticancer research 1999;19(1A):333-6.
1999: Manfred Volm; Reet Koomägi; Jürgen Mattern
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.
Anticancer research 1999;19(1B):651-5.
1998: Jürgen Mattern; Reet Koomägi; Manfred Volm
Xenotransplantability of human cancers in mice.
Journal of the National Cancer Institute 1998;90(22):1747-9.
1998: Manfred Volm; Jürgen Mattern; R Koomagi
Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors.
International journal of oncology 1998;13(5):975-9.
1998: Manfred Volm; Jürgen Mattern; Reet Koomägi
Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas.
Clinical & experimental metastasis 1998;16(7):595-602.
1998: Jürgen Mattern; Uta Eichhorn; Bernd Kaina; Manfred Volm
O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts.
International journal of cancer. Journal international du cancer 1998;77(6):919-22.
1998: Manfred Volm; Reet Koomägi; Jürgen Mattern
Prognostic value of p16INK4A expression in lung adenocarcinoma.
Anticancer research 1998;18(4A):2309-12.
1998: Jürgen Mattern; Reet Koomägi; Manfred Volm
Smoking-related increase of O6-methylguanine-DNA methyltransferase expression in human lung carcinomas.
Carcinogenesis 1998;19(7):1247-50.
1998: Jürgen Mattern; Gerd Stammler; R Koomagi; Diethelm Wallwiener; M Kaufmann; Manfred Volm
Spontaneous apoptosis in ovarian cancer: an unfavorable prognostic factor.
International journal of oncology 1998;12(2):351-4.
1997: Manfred Volm; Jürgen Mattern; Reet Koomägi
Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance.
Anti-cancer drugs 1997;8(10):931-6.
1997: Jürgen Mattern; Reet Koomägi; Manfred Volm
Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density.
Anticancer research 1997;17(3C):2249-52.
1997: Manfred Volm; Reet Koomägi; Jürgen Mattern; Gerd Stammler
Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas.
European journal of cancer (Oxford, England : 1990) 1997;33(4):691-3.
1997: Manfred Volm; Reet Koomägi; Jürgen Mattern
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer.
International journal of cancer. Journal international du cancer 1997;74(1):64-8.
1997: Manfred Volm; Reet Koomägi; Jürgen Mattern; Gerd Stammler
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
British journal of cancer 1997;75(12):1774-8.
1997: Manfred Volm; Reet Koomägi; Jürgen Mattern; Gerd Stammler
Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro.
Anticancer research 1997;17(1A):99-103.
1997: Jürgen Mattern; Gerd Stammler; R Koomagi; Diethelm Wallwiener; M Kaufmann; Manfred Volm
Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma.
Anticancer research 1997;17(1B):621-4.
1996: Reet Koomägi; Gerd Stammler; C Manegold; Jürgen Mattern; Manfred Volm
Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer.
Cancer letters 1996;110(1-2):129-36.
1996: Jürgen Mattern; Friedrich Kallinowski; Christian Herfarth; Manfred Volm
Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer.
International journal of cancer. Journal international du cancer 1996;67(1):20-3.
1996: Manfred Volm; R Koomagi; M Kaufmann; Jürgen Mattern; Gerd Stammler
Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas.
Clinical & experimental metastasis 1996;14(3):209-14.
1996: Jürgen Mattern; Reet Koomägi; Manfred Volm
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.
British journal of cancer 1996;73(7):931-4.
1996: Manfred Volm; Reet Koomägi; G van Kaick; Jürgen Mattern
[Vascular thickness and cytostatic-resistant bronchial carcinoma].
Deutsche medizinische Wochenschrift (1946) 1996;121(10):291-4.
1996: Gerd Stammler; E W Pommerenke; U Masanek; Jürgen Mattern; Manfred Volm
Messenger RNA expression of resistance factors in human tumor cell lines after single exposure to radiation.
Journal of experimental therapeutics & oncology 1996;1(1):39-48.
1996: Manfred Volm; Jürgen Mattern
Resistance mechanisms and their regulation in lung cancer.
Critical reviews in oncogenesis 1996;7(3-4):227-44.
1996: Manfred Volm; Reet Koomägi; Jürgen Mattern
Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.
Anticancer research 1996;16(1):213-7.
1995: Manfred Volm; Jürgen Mattern; Gerd Stammler
Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers.
Anticancer research 1995;15(6B):2607-9.
1995: Manfred Volm; Jürgen Mattern; Gerd Stammler; Brigitte Royer-Pokora; S Schneider; Angela Weirich; R Ludwig
Expression of resistance-related proteins in nephroblastoma after chemotherapy.
International journal of cancer. Journal international du cancer 1995;63(2):193-7.
1995: Gerd Stammler; E W Pommerenke; Jürgen Mattern; Manfred Volm
Effects of single doses of irradiation on the expression of resistance-related proteins in murine NIH 3T3 and human lung carcinoma cells.
Carcinogenesis 1995;16(9):2051-5.
1995: Manfred Volm; Reet Koomägi; Jürgen Mattern; Gerd Stammler
Heat shock (hsp70) and resistance proteins in non-small cell lung carcinomas.
Cancer letters 1995;95(1-2):195-200.
1995: Manfred Volm; S Hecker; Axel Sauerbrey; Jürgen Mattern
Predictive value of statin, a G0-associated cell cycle protein, in childhood acute lymphoblastic leukemia.
International journal of cancer. Journal international du cancer 1995;64(3):166-70.
1995: Jürgen Mattern; Axel Sauerbrey; Manfred Volm
p53 protein detected by two different antibodies: relationship to proliferation and prognosis in acute lymphoblastic leukemia.
Anticancer research 1995;15(3):1043-7.
1994: Manfred Volm; G van Kaick; Jürgen Mattern
Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases.
Clinical & experimental metastasis 1994;12(4):329-34.
1994: Jürgen Mattern; Manfred Volm
Detection of resistance proteins in matched primary lung tumors and lymph node metastases.
Anticancer research 1994;14(2A):417-9.
1994: E Pommerenke; Jürgen Mattern; Manfred Volm
Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo.
Journal of cancer research and clinical oncology 1994;120(7):422-6.
1993: Manfred Volm; Jürgen Mattern
Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
Anticancer research 1993;13(6A):2021-5.
1993: Manfred Volm; M Kästel; Jürgen Mattern; T Efferth
Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Cancer 1993;71(12):3981-7.
1992: Manfred Volm; Jürgen Mattern
Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas.
Anticancer research 1992;12(6B):2293-6.
1992: Manfred Volm; Jürgen Mattern
Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits.
Carcinogenesis 1992;13(11):1947-50.
1992: Jürgen Mattern; Manfred Volm
[The individualized therapy of tumors].
Deutsche medizinische Wochenschrift (1946) 1992;117(44):1685-9.
1992: Manfred Volm; T Efferth; Jürgen Mattern; E W Pommerenke
Resistance mechanisms in murine tumors with acquired multidrug resistance.
Arzneimittel-Forschung 1992;42(9):1163-8.
1992: Manfred Volm; Jürgen Mattern; B Samsel
Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors.
Cancer 1992;70(4):764-9.
1992: Manfred Volm; Jürgen Mattern; T Efferth; E W Pommerenke
Expression of several resistance mechanisms in untreated human kidney and lung carcinomas.
Anticancer research 1992;12(4):1063-7.
1992: Jürgen Mattern; Manfred Volm
Prediction of drug resistance in human tumors using immunohistochemical techniques.
Anticancer research 1992;12(2):413-8.
1992: T Efferth; Jürgen Mattern; Manfred Volm
Immunohistochemical detection of P glycoprotein, glutathione S transferase and DNA topoisomerase II in human tumors.
Oncology 1992;49(5):368-75.
1992: Manfred Volm; T Efferth; Jürgen Mattern
Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Anticancer research 1992;12(1):11-20.
1991: Manfred Volm; Jürgen Mattern; B Samsel
Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers.
British journal of cancer 1991;64(4):700-4.
1991: Manfred Volm; Jürgen Mattern; B Samsel
[The prevalence of cytostatic-resistant lung tumors in smokers].
Deutsche medizinische Wochenschrift (1946) 1991;116(35):1303-6.
1991: E W Pommerenke; Jürgen Mattern; U Traugott; Manfred Volm
[Reversal of multidrug resistance with (R)-verapamil in vitro and in vivo].
Arzneimittel-Forschung 1991;41(8):855-8.
1991: Manfred Volm; E W Pommerenke; T Efferth; H Löhrke; Jürgen Mattern
Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro.
Cancer 1991;67(10):2484-9.
1991: T Efferth; T Klett; Jürgen Mattern; H Osswald; E W Pommerenke; M Stöhr; Manfred Volm
Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo.
Anticancer research 1991;11(3):1275-9.
1991: Manfred Volm; Jürgen Mattern; E W Pommerenke
Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.
Anticancer research 1991;11(2):579-85.
1990: Manfred Volm; B Samsel; Jürgen Mattern
Relationship between chemoresistance of lung tumours and cigarette smoking.
British journal of cancer 1990;62(2):255-6.
1990: Jürgen Mattern; M Bak; Manfred Volm
Intrinsic and acquired multidrug resistance in human lung carcinomas grown in nude mice.
Anticancer research 1990;10(1):177-80.
1990: Manfred Volm; Heide Zerban; Jürgen Mattern; T Efferth
Overexpression of P-glycoprotein in rat hepatocellular carcinomas induced with N-nitrosomorpholine.
Carcinogenesis 1990;11(1):169-72.
1989: Jürgen Mattern; M Bak; K H Hoever; Manfred Volm
Radiosensitivity of drug-resistant human tumour xenografts.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(12):870-2.
1989: J Schneider; M Bak; T Efferth; M Kaufmann; Jürgen Mattern; Manfred Volm
P-glycoprotein expression in treated and untreated human breast cancer.
British journal of cancer 1989;60(6):815-8.
1989: Jürgen Mattern; Manfred Volm
[P glycoprotein as a resistance marker in tumors].
Deutsche medizinische Wochenschrift (1946) 1989;114(50):1979-81.
1989: Manfred Volm; T Efferth; Jürgen Mattern
Acquired drug resistance in human lung carcinoma xenografts.
Arzneimittel-Forschung 1989;39(8):828-31.
1989: Manfred Volm; K Kayser; Jürgen Mattern
[Demonstration of independent cellular prognostic factors in squamous cell carcinoma of the lung].
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(8):587-92.
1989: Jürgen Mattern; L Edler; Manfred Volm
Quantitative analysis of resistance and cross-resistance to cytotoxic agents by tumour cell lines.
Anticancer research 1989;9(4):833-6.
1989: Manfred Volm; M Bak; Jürgen Mattern
Intrinsic multidrug resistance in human lung carcinomas grown in nude mice.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(7):524-6.
1989: M Bak; Jürgen Mattern; Manfred Volm
Comparative histopathology of human epidermoid lung carcinoma xenografts.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(7):485-6.
1989: Manfred Volm; M Bak; T Efferth; Jürgen Mattern
Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface-membrane glycoprotein.
Journal of cancer research and clinical oncology 1989;115(1):17-24.
1988: Manfred Volm; M Bak; T Efferth; Jürgen Mattern
Induced multidrug-resistance in murine sarcoma 180 cells grown in vitro and in vivo and associated changes in expression of multidrug-resistance DNA-sequences and membrane glycoproteins.
Anticancer research 1988;8(6):1169-78.
1988: Manfred Volm; M Bak; Jürgen Mattern
Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins.
Arzneimittel-Forschung 1988;38(8):1189-93.
1988: Jürgen Mattern; M Bak; K H Hoever; Manfred Volm
Development of drug resistance in a human epidermoid lung carcinoma xenograft line.
British journal of cancer 1988;58(1):30-3.
1988: Manfred Volm; M Bak; T Efferth; B Lathan; Jürgen Mattern
Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4.
Anticancer research 1988;8(4):531-5.
1988: Manfred Volm; M Bak; Eric W Hahn; Jürgen Mattern; E Weber
DNA and S-phase distribution and incidence of metastasis in human primary lung carcinoma.
Cytometry 1988;9(2):183-8.
1988: Manfred Volm; P Drings; Eric W Hahn; Jürgen Mattern
Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test.
British journal of cancer 1988;57(2):198-200.
1988: Manfred Volm; Jürgen Mattern; T Müller; P Drings
Flow cytometry of epidermoid lung carcinomas: relationship of ploidy and cell cycle phases to survival. A five-year follow up study.
Anticancer research 1988;8(1):105-12.
1987: Manfred Volm; P Drings; W Kleine; Jürgen Mattern
Flow cytometry as a tool for the prognostic assessment of patients with lung and ovarian carcinomas.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1987;163(12):791-4.
1987: Manfred Volm; Jürgen Mattern
Clinical prognostic relevance of growth of human adenocarcinomas of the lung in nude mice.
Anticancer research 1987;7(6):1129-32.
1987: Jürgen Mattern; M Bak; Manfred Volm
Occurrence of a multidrug-resistant phenotype in human lung xenografts.
British journal of cancer 1987;56(4):407-11.